NetworkNewsBreaks – Galectin Therapeutics, Inc. (NASDAQ: GALT) Receives Decision to Grant From Japanese Patent Office for GR-MD-02 Composition of Matter Patent
Galectin Therapeutics (NASDAQ: GALT) this morning said it has received a decision from the Japanese Patent Office to grant its patent application for "Composition of Novel Carbohydrate Drug for Treatment of Human Diseases." Upon issuance, the patent will expand coverage of the company's lead compound, GR-MD-02, to Japan through 2032. "The allowance of these claims in Japan further strengthens the protection of the intellectual property behind our proprietary compound, GR-MD-02. This is especially important in Japan, which was recently declared the second most attractive drug market in the world," Galectin CEO and chief medical officer Peter G. Traber, M.D. stated…







